Bionexus Gene Lab CORP (BGLC) — SEC Filings

Overview

Bionexus Gene Lab CORP (BGLC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: BioNexus Gene Lab Corp. filed an 8-K on December 23, 2025, reporting an event that occurred on December 19, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, acquisitions, or executive changes.

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 6 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Bionexus Gene Lab CORP is neutral.

Filing Type Overview

Bionexus Gene Lab CORP (BGLC) has filed 28 8-K, 3 DEF 14A, 6 10-Q, 2 10-K/A, 2 10-K, 1 8-K/A, 1 10-Q/A, 1 SC 13D with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

• 8-K Filing — 8-K · Dec 30, 2025
• BioNexus Gene Lab Corp Files 8-K — 8-K · Dec 23, 2025 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on December 23, 2025, reporting an event that occurred on December 19, 2025. The filing is categorized under 'Other Events'
• BioNexus Gene Lab Sets Virtual Annual Meeting, Seeks Director Re-election — DEF 14A · Dec 3, 2025 Risk: low
  BioNexus Gene Lab Corp. (BGLC) is holding its Annual Meeting of Stockholders on December 24, 2025, virtually at 9:00 a.m. Eastern Time. Key proposals include th
• 8-K Filing — 8-K · Dec 2, 2025
• BioNexus Narrows Q3 Loss, But 9-Month Deficit Widens Amid Revenue Dip — 10-Q · Nov 14, 2025 Risk: high
  BioNexus Gene Lab Corp. (BGLC) reported a net loss of $708,991 for the three months ended September 30, 2025, a significant improvement from the $1,345,370 net
• 8-K Filing — 8-K · Nov 13, 2025
• BioNexus Gene Lab Corp. Files 8-K with Key Agreements and Sales — 8-K · Nov 12, 2025 Risk: medium
  BioNexus Gene Lab Corp. filed an 8-K on November 12, 2025, reporting on several key events. These include entering into a material definitive agreement, unregis
• BioNexus Gene Lab Corp Files 8-K — 8-K · Oct 23, 2025 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on October 23, 2025, reporting events as of October 20, 2025. The filing primarily concerns Regulation FD Disclosure and in
• BioNexus Gene Lab Corp Q2 2025 10-Q Filed — 10-Q · Aug 18, 2025 Risk: medium
  BioNexus Gene Lab Corp filed a 10-Q for the period ending June 30, 2025. The company, incorporated in Wyoming, operates in medical laboratories and is based in
• BioNexus Gene Lab Corp. Files 8-K — 8-K · Jul 30, 2025 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on July 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporated
• BioNexus Gene Lab Corp. Elects New Directors — 8-K · Jun 23, 2025 Risk: medium
  BioNexus Gene Lab Corp. announced on June 17, 2025, a change in its board of directors. The company elected two new directors, Mr. Jianjun Li and Mr. Jianjun Li
• BioNexus Gene Lab Corp Q1 2025 10-Q Filing — 10-Q · May 15, 2025 Risk: medium
  BioNexus Gene Lab Corp filed a 10-Q for the period ending March 31, 2025. The company's business activities include investment holding and provision for genomic
• BioNexus Gene Lab Corp. Faces Delisting Concerns — 8-K · Apr 30, 2025 Risk: high
  BioNexus Gene Lab Corp. filed an 8-K on April 30, 2025, to report its notice of delisting or failure to satisfy a continued listing rule or standard, along with
• BioNexus Gene Lab Corp Files 2024 Annual Report Amendment — 10-K/A · Apr 29, 2025 Risk: low
  BioNexus Gene Lab Corp filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Wyoming and he
• BioNexus Gene Lab Corp Files 2024 10-K — 10-K · Apr 15, 2025 Risk: medium
  BioNexus Gene Lab Corp filed its 2024 10-K on April 15, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Wyoming, opera
• BioNexus Gene Lab Corp. Files 8-K on Security Holder Rights — 8-K · Apr 10, 2025 Risk: medium
  BioNexus Gene Lab Corp. filed an 8-K on April 10, 2025, reporting a material modification to the rights of its security holders as of April 7, 2025. The filing
• BioNexus Gene Lab Corp Files 8-K on Corporate Changes — 8-K · Apr 3, 2025 Risk: medium
  BioNexus Gene Lab Corp. filed an 8-K on April 3, 2025, reporting material modifications to security holder rights and amendments to its articles of incorporatio
• BioNexus Gene Lab Corp. Files 8-K on Shareholder Vote Matters — 8-K · Mar 25, 2025 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on March 25, 2025, reporting a submission of matters to a vote of security holders on March 19, 2025. The company, incorpor
• BioNexus Gene Lab Corp. Files 8-K — 8-K · Mar 7, 2025 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on March 7, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compan
• BioNexus Gene Lab Corp. Files 8-K — 8-K · Mar 5, 2025 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on March 5, 2025, reporting other events and financial statements. The company, incorporated in Wyoming, is based in Kuala
• BioNexus Gene Lab Corp Files Definitive Proxy Statement — DEF 14A · Feb 27, 2025 Risk: low
  BioNexus Gene Lab Corp. filed a Definitive Proxy Statement (DEF 14A) on February 27, 2025, for the fiscal year ending December 31, 2024. The filing, with SEC fi
• BioNexus Gene Lab Corp. Files 8-K on Equity Sales & Bylaw Changes — 8-K · Feb 14, 2025 Risk: medium
  BioNexus Gene Lab Corp. filed an 8-K on February 14, 2025, reporting on unregistered sales of equity securities and material modifications to security holder ri
• BioNexus Gene Lab Corp. Faces Delisting Concerns — 8-K · Jan 2, 2025 Risk: high
  BioNexus Gene Lab Corp. filed an 8-K on January 2, 2025, reporting a notice of delisting or failure to meet continued listing standards as of December 27, 2024.
• BioNexus Gene Lab Corp Files Q3 2024 10-Q — 10-Q · Nov 15, 2024 Risk: medium
  BioNexus Gene Lab Corp filed its Q3 2024 10-Q report on November 15, 2024, covering the period ending September 30, 2024. The company, incorporated in Wyoming,
• BioNexus Gene Lab Corp. Faces Delisting Concerns — 8-K · Nov 8, 2024 Risk: high
  BioNexus Gene Lab Corp. filed an 8-K on November 8, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The filing also covers
• BioNexus Gene Lab Corp. Reports Board and Officer Changes — 8-K · Oct 15, 2024 Risk: medium
  BioNexus Gene Lab Corp. announced on October 9, 2024, a change in its board of directors. The company filed an 8-K report detailing the departure of certain off
• BioNexus Gene Lab Corp. Files 8-K on Corporate Matters — 8-K · Oct 10, 2024 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on October 10, 2024, reporting on matters submitted to a vote of security holders and other events that occurred on October
• BioNexus Gene Lab Corp. Files 8-K for Material Agreement — 8-K · Sep 25, 2024 Risk: medium
  BioNexus Gene Lab Corp. announced on September 25, 2024, that it entered into a material definitive agreement on September 23, 2024. The company, incorporated i
• BioNexus Gene Lab Corp Files 8-K — 8-K · Sep 18, 2024 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on September 18, 2024, reporting an event that occurred on September 14, 2024. The filing is a current report pursuant to S
• BioNexus Gene Lab Corp Files Definitive Proxy Statement — DEF 14A · Sep 16, 2024 Risk: low
  BioNexus Gene Lab Corp. filed a Definitive Proxy Statement (DEF 14A) on September 16, 2024, for the fiscal year ending December 31, 2024. The company, incorpora
• BioNexus Gene Lab Corp Files 8-K — 8-K · Sep 12, 2024 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on September 12, 2024, reporting an event on September 11, 2024. The filing is categorized under Regulation FD Disclosure a
• BioNexus Gene Lab Corp. Files 8-K, Changes Fiscal Year — 8-K · Sep 5, 2024 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on September 5, 2024, reporting a change in its fiscal year end to December 31st. This filing also includes financial state
• BioNexus Gene Lab Corp Files 8-K — 8-K · Aug 28, 2024 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on August 28, 2024, reporting events as of August 27, 2024. The filing primarily concerns Regulation FD Disclosure and incl
• BioNexus Gene Lab Corp. Enters Material Definitive Agreement — 8-K · Aug 26, 2024 Risk: medium
  BioNexus Gene Lab Corp. announced on August 26, 2024, that it has entered into a material definitive agreement. The company, incorporated in Wyoming with its pr
• BioNexus Gene Lab Corp Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: low
  BioNexus Gene Lab Corp filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Wyoming, operates in the medical laboratories sector. It
• BioNexus Gene Lab Corp Files 8-K/A Amendment — 8-K/A · Jul 5, 2024 Risk: medium
  BioNexus Gene Lab Corp. filed an amendment (8-K/A) on July 5, 2024, to a report originally dated March 26, 2024. The amendment pertains to the departure of dire
• BioNexus Gene Lab Corp Files 2022 Annual Report Amendment — 10-K/A · May 31, 2024 Risk: low
  BioNexus Gene Lab Corp filed an amendment (10-K/A) on May 31, 2024, for its fiscal year ending December 31, 2022. The company, incorporated in Wyoming, operates
• BioNexus Gene Lab Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  BioNexus Gene Lab Corp (BGLC) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. BioNexus Gene Lab Corp filed a 10-Q report for the period ending Mar
• BioNexus Gene Lab Corp. Faces Delisting Notice — 8-K · May 9, 2024 Risk: high
  BioNexus Gene Lab Corp. filed an 8-K on May 8, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated
• BioNexus Gene Lab Corp Files 8-K — 8-K · Apr 18, 2024 Risk: low
  BioNexus Gene Lab Corp. filed an 8-K on April 18, 2024, to report on other events and financial statements. The filing details the company's incorporation in Wy
• BioNexus Gene Lab Corp Files 2023 Annual Report on Form 10-K — 10-K · Apr 16, 2024 Risk: medium
  BioNexus Gene Lab Corp (BGLC) filed a Annual Report (10-K) with the SEC on April 16, 2024. BioNexus Gene Lab Corp filed its 2023 Form 10-K on April 16, 2024, re
• BioNexus Gene Lab Corp. Files 8-K on Officer/Director Changes — 8-K · Apr 1, 2024 Risk: medium
  BioNexus Gene Lab Corp. filed an 8-K on March 26, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment
• BioNexus Gene Lab Corp Files 10-Q/A for Period Ending September 30, 2023 — 10-Q/A · Mar 26, 2024 Risk: medium
  BioNexus Gene Lab Corp (BGLC) filed a Amended Quarterly Report (10-Q/A) with the SEC on March 26, 2024. The company filed an amended 10-Q for the period ending
• Insider Group Acquires 100% of BioNexus Gene Lab Corp. Shares — SC 13D · Jan 17, 2024
  A group of individuals, including Lai Soo Kow, has collectively acquired beneficial ownership of 10,000,000 shares of BioNexus Gene Lab Corp. (BGLC) common stoc

Risk Profile

Risk Assessment: Of BGLC's 40 recent filings, 5 were flagged as high-risk, 16 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Bionexus Gene Lab CORP's most recent 10-Q filing (Nov 14, 2025):

• Revenue: $6,941,151
• Net Income: -$1,948,490
• EPS: N/A
• Debt-to-Equity: 0.12
• Cash Position: $1,357,092
• Operating Margin: N/A
• Total Assets: $7,621,228
• Total Debt: $804,966

Key Executives

• Su-Leng Tan Lee
• Muhammad Azrul bin Abdul Hamid
• Jook Yuen Low
• Chee Keong Yap
• Jianjun Li
• Mr. Wong Kim Hai

Industry Context

BioNexus Gene Lab Corp operates in the biotechnology and gene laboratory sector, a field characterized by rapid scientific advancements and significant research and development investment. The industry is highly competitive, with numerous companies vying for market share and innovation leadership. Trends include increasing focus on personalized medicine, gene editing technologies, and diagnostic tools.

Top Tags

corporate-governance (7) · sec-filing (6) · 8-K (5) · 10-Q (5) · disclosure (4) · financials (4) · delisting (4) · medical-laboratories (4) · listing-standards (3) · regulatory-filing (3)

Key Numbers

• Annual Meeting Date: 2025-12-24 — Date of the virtual Annual Meeting of Stockholders
• Record Date: 2025-11-28 — Date for determining stockholders entitled to vote
• Shares of Common Stock Outstanding: 2,363,836 — Total shares entitled to vote as of the Record Date
• Holders of Record: 294 — Approximate number of stockholders as of the Record Date
• Quorum Requirement: 1/3 — Fraction of outstanding shares required for a quorum
• Equity Incentive Plan Year: 2025 — Year of the Equity Incentive Plan proposed for approval
• Auditor Re-appointment Year: 2026 — Year until which auditors are to hold office
• Meeting Start Time: 9:00 a.m. — Eastern Time for the virtual Annual Meeting
• Net Loss (Q3 2025): $708,991 — Decreased from $1,345,370 in Q3 2024, a 47.3% improvement.
• Net Loss (9 Months 2025): $1,948,490 — Increased from $1,250,023 in 9 Months 2024, a 55.9% worsening.
• Revenue (Q3 2025): $2,543,823 — Slightly decreased from $2,630,376 in Q3 2024, a 3.3% decline.
• Revenue (9 Months 2025): $6,941,151 — Slightly decreased from $6,986,791 in 9 Months 2024, a 0.65% decline.
• Total Operating Expenses (Q3 2025): $1,187,954 — Decreased significantly from $2,129,685 in Q3 2024, a 44.3% reduction.
• Cash and Cash Equivalents (Sep 30, 2025): $1,357,092 — Decreased from $2,886,966 at the beginning of the period, a 53% drop.
• Investments in Equity Securities (Sep 30, 2025): $237,760 — Decreased from $1,265,166 at Dec 31, 2024, an 81.2% reduction.

Related Companies

BGLL · BNGL

Frequently Asked Questions